The Pharma Data

JUNE 18, 2025

While localized prostate cancer boasts a five-year survival rate above 90% , that figure drops precipitously to approximately 31% for metastatic disease. It will enroll patients with mCRPC who have experienced disease progression during or after ARPI therapy.

Trials

Drug Target Review

JULY 31, 2025

The scalability and cost-effectiveness of recombinant production have also democratised access to these improved antibodies, allowing academic labs and small biotech startups to leverage the same advanced tools once limited to large pharmaceutical companies.

Engineering

Drug Patent Watch

DECEMBER 9, 2024

High-Throughput Screening: Modern Technology Meets Natural Products Advanced technologies now allow researchers to rapidly test thousands of natural compounds against specific disease targets. This approach has led to the discovery of numerous potential drug candidates.

Drugs

ACTO

AUGUST 11, 2025

GDS’s universe-based approach and rare disease expertise, combined with ACTO’s Intelligent Field Excellence (IFE) platform, allow us to empower organizations to prioritize smarter, connect deeper, and ultimately reach more of the right patients faster,” said JoJo Kalita , ACTO’s Vice President of Partnerships and the ACTOverse.

Disease

SugarCone Biotech

JUNE 19, 2025

Finally, while there are clear front runners among the pharmaceutical companies developing targeted therapeutics for these antigens there are also emerging biotechs aggressively pursuing these targets. Over 70% of new patients are diagnosed with stage IV disease, also called extensive stage disease (ES-SCLC).

Therapies

The Pharma Data

JUNE 24, 2025

Extending their 16-year collaboration for another three years, this renewed alliance is designed to accelerate the translation of basic scientific research into practical applications across the pharmaceutical value chain. This progress is driven by the dedicated efforts and strong collaborations among innovators of science and business.

Pharma R&D

Drug Target Review

MARCH 4, 2025

A personalised approach to obesity treatment Traditional obesity treatments have often followed a one-size-fits-all model, despite mounting evidence that obesity is not a singular disease but rather a collection of subtypes. This growing health challenge increases the risk of diabetes, heart disease, and other conditions.

Therapies

DrugBank

JUNE 18, 2025

This means pharmaceutical companies must remain vigilant and adaptable to comply with evolving regulations. Regulatory agencies require pharmaceutical companies to submit preclinical and clinical trial data covering toxicology, pharmacokinetics, pharmacodynamics, and long-term safety monitoring.

Drug Development

Codon

NOVEMBER 3, 2024

Physicians working in the early 20th century had little choice but to treat the world’s most rampant infectious disease with methods such as these. But even now, more than a century later, TB remains the deadliest infectious disease on Earth, killing about 1.2 million people every year. Can We Lay This Scourge to Rest?

Vaccine

BioPharma Drive: Drug Pricing

JUNE 11, 2025

Ibtrozi has also shown the ability to help people whose cancer has spread to the brain, a leading cause of disease progression, the company said. Published June 11, 2025 Ben Fidler Senior Editor post share post print email license The FDA on June 11, 2025 approved Nuvation's Ibtrozi for ROS1-positive non-small cell lung cancer.

FDA

Drug Patent Watch

JANUARY 14, 2025

Key Stakeholders in Pharmaceutical Negotiations Successful negotiations in the pharmaceutical industry require a deep understanding of the various stakeholders involved. These may include: Pharmaceutical companies (big pharma and biotech firms) Contract research organizations (CROs) Regulatory bodies (e.g.,

Pharmaceuticals

SugarCone Biotech

JULY 6, 2025

Finally, while there are clear front runners among the pharmaceutical companies developing targeted therapeutics for these antigens there are also emerging biotechs aggressively pursuing these targets. Each target and each therapeutic modality induces varying degrees of clinical efficacy, as well as causing toxicities.

Drug Development

The Pharma Data

JUNE 20, 2025

“This positive CHMP opinion reinforces darolutamide’s potential to become a leading therapy across various stages of prostate cancer and underscores our commitment to advancing innovative solutions for men living with this disease,” she stated. In 2022 alone, approximately 1.5 million annually by 2040.

Trials

Drug Target Review

MAY 26, 2025

Even large pharmaceutical companies often rely on CROs for their expertise and resources. According to Galbraith, the in-depth scientific knowledge required to support innovative drug development is often not cost-effective for companies to maintain internally.

Drug Development

BioPharma Drive: Drug Pricing

JULY 16, 2025

On a conference call held Wednesday afternoon, Sarepta CEO Doug Ingram said that "failure to adapt" to recent setbacks "would risk our long-term viability as an organization and decrease the opportunity to bring the greatest benefit to the greatest number of patients living with rare disease." By Jonathan Gardner • Sept.

Therapies

BioPharma Drive: Drug Pricing

JULY 10, 2025

Spencer Platt via Getty Images The first marketed treatment for the insatiable hunger associated with Prader-Willi disease is selling more quickly than Wall Street analysts expected, an early, but encouraging sign of demand. The disease, which affects an estimated 10,000 to 20,000 people in the U.S., By Jonathan Gardner • Sept.

Drugs

BioPharma Drive: Drug Pricing

JUNE 24, 2025

In a filing with the Securities and Exchange Commission in March, Lexeo said it was seeking “ business development opportunities ” for its portfolio of Alzheimer’s disease treatments, one of which it has brought into the clinic. Now, Lexeo is lending its expertise to a new biotechnology company, which its CEO R.

RNA

BioPharma Drive: Drug Pricing

JULY 9, 2025

has agreed to pay $10 billion to buy London-based Verona Pharma, scooping up a potential multibillion-dollar new drug to treat chronic obstructive pulmonary disease in a deal announced Wednesday. Alamy Merck & Co. The Food and Drug Administration approved Verona’s Ohtuvayre in June 2024 for maintenance treatment of COPD in adults.

Clinical Trials

The Pharma Data

JUNE 6, 2025

The Strategic Role of CSOs in a Changing Pharmaceutical Landscape Pharmaceutical contract sales outsourcing is no longer viewed as a temporary or stop-gap measure. CNS Disorders and Autoimmune Diseases : Where nuanced communication and long-term patient management are key. Equally important is regulatory compliance.

Pharmaceutical Companies

Codon

JULY 14, 2025

And some of the remedies are still practiced today: the treatment for Guinea-worm disease was, and still is , to wrap the emerging end of the worm around a stick and slowly pull it out. estimated to be about 29 million people) took daily aspirin to prevent cardiovascular disease. As a piece of history, it’s fantastic.

Treatment

The Pharma Data

JUNE 24, 2025

Regeneron Unveils Groundbreaking $200 Million Donation Matching Program to Expand Patient Access to Vision-Saving Treatments Regeneron Pharmaceuticals , a leader in biotechnology and a longtime advocate for equitable healthcare access, has announced a bold new philanthropic initiative designed to support patients facing debilitating eye diseases.

Treatment

The Pharma Data

JULY 2, 2025

Genmab Announces Leadership Transition as Chief Legal Officer Birgitte Stephensen Retires, Greg Mueller Appointed Successor Genmab A/S (Nasdaq: GMAB), a leading international biotechnology company focused on antibody-based therapeutics for cancer and other serious diseases, today announced a major leadership transition within its executive team.

Compliance

The Pharma Data

AUGUST 1, 2025

In 2015, it became the first publicly traded biotech or pharmaceutical company to adopt Public Benefit Corporation (PBC) status. Through initiatives like lung bioengineering, xenotransplantation, and 3D organ printing, the company is attempting to solve some of the most pressing challenges in end-stage organ disease.

Government

BioPharma Drive: Drug Pricing

APRIL 28, 2025

Pharmaceutical companies are turning to integrated RWD approaches to overcome challenges in rare disease research.

Disease

BioPharma Drive: Drug Pricing

OCTOBER 23, 2023

The Swiss pharmaceutical company has agreed to buy Televant, a company set up by Roivant and Pfizer to develop a promising inflammatory bowel disease treatment.

Disease

BioPharma Drive: Drug Pricing

APRIL 5, 2024

The German pharmaceutical company is “streamlining” its custom-facing teams behind Cyltezo, a copycat version of AbbVie’s immune disease drug Humira.

Biosimilars

Drug Patent Watch

JULY 27, 2021

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong. The FDA is….

Pharmaceutical Companies

Drug Patent Watch

JANUARY 19, 2024

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The FDA is… The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong.

Pharmaceutical Companies

Drug Patent Watch

SEPTEMBER 28, 2023

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The FDA is… The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong.

Pharmaceutical Companies

Drug Patent Watch

JULY 27, 2023

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The FDA is… The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong.

Pharmaceutical Companies

Drug Patent Watch

JANUARY 19, 2023

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The FDA is… The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong.

Pharmaceutical Companies

Drug Patent Watch

SEPTEMBER 27, 2020

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong. The FDA is….

Pharmaceutical Companies

Conversations in Drug Development Trends

MAY 14, 2024

By: Amy Raymond, Derek Ansel, Nathan Chadwick, & Juliane Mills When choosing a CRO for a rare disease study, what truly sets them apart is their methodology: the CRO’s mindset, their approach to each unique study, and their agility in navigating the inherent complexities of rare disease research. Common goals empower change.

Disease

Drug Patent Watch

SEPTEMBER 29, 2022

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong. The FDA is….

Pharmaceutical Companies

Drug Patent Watch

JULY 27, 2022

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong. The FDA is….

Pharmaceutical Companies

Drug Patent Watch

JANUARY 19, 2022

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong. The FDA is….

Pharmaceutical Companies

Drug Patent Watch

SEPTEMBER 28, 2021

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong. The FDA is….

Pharmaceutical Companies